Abstract:Objective:To evaluate the value of combined detection of serum pepsinogen (PG) and gastrin 17 (G-17) in detection of atrophic gastritis (AG) in asymptomatic population with high-risk of gastric cancer.Methods:From July 2016 to December 2017, a total of 373 asymptomatic population with high-risk of gastric cancer and lived in central city of Shanghai were selected. According to results of endoscopy and histopathology, the residents were divided into non-atrophic gastritis (NAG) group, mild to moderate atrophic gastritis (MAG) group and severe atrophic gastritis (SAG) group. The serum levels of PGⅠ, PGⅡ and G-17 were measured by enzyme linked immunosorbent assay. Kruskal-Wallis H test, Mann-Whitney U test, chi square test and Z test were used for statistical analysis. Binary logistic regression analysis were used to analyze the value of serum PGR, G-17 and their combination (joint predictor) in prediction of SAG. Results:Among the 373 asymptomatic population with high-risk of gastric cancer, there were 146 cases in NAG group, 136 cases in MAG group and 91 cases in SAG group. There were no statistically significant differences in gender, age, body mass index and infection rate of H. pylori immunoglobulin G among the three groups of asymptomatic population with high-risk of gastric cancer. The serum levels of PGⅠ, PGR and G-17 of SAG group were all lower than those of NAG group and MAG group (PGⅠ: 92.73 pmol/L, 20.39 pmol/L to 119.28 pmol/L vs. 133.69 pmol/L, 103.44 pmol/L to 183.70 pmol/L and 120.64 pmol/L, 23.37 pmol/L to 173.91 pmol/L ; PGR: 7.40, 1.63 to 9.52 vs. 13.71, 12.38 to 16.73 and 10.06, 4.49 to 15.87; G-17: 2.31 pmol/L, 0.59 pmol/L to 3.24 pmol/L vs. 4.59 pmol/L, 1.96 pmol/L to 10.86 pmol/L and 12.51 pmol/L, 11.96 pmol/L to 15.60 pmol/L), and the differences were statistically significant ( UPGⅠ=8 262.500 and 3 360.000, P=0.024, P<0.01; UPGR=4 999.000 and 2 377.500, both P<0.01; UG-17=3 748.500 and 1 688.000, both P<0.01). The results of binary logistic regression analysis indicated that serum PGR ( β=-0.423, odds ratio ( OR)=0.655, 95% CI 0.516 to 0.885, P<0.01) and G-17 ( β=-0.509, OR=0.601, 95% CI 0.415 to 0.859, P<0.01) were both protective factors to avoid SAG development. And the combination of predictive factors of serum PGR and G-17 for SAG was L=3.621-0.423×PGR-0.509×G-17. The receiver operating characteristic (ROC) area under the curve (AUC) values of serum PGR, G-17 and combined predictors to predict SAG were 0.714, 0.655 and 0.859, respectively. And the sensitivity of predicting SAG was 91.11%, 100.00% and 100.00%, respectively; the specificity was 83.56%, 95.74% and 99.29% respectively. The ROC AUC value of combined predictors to predict SAG was higher than those of PGR or G-17 alone, and the differences were statistically significant ( Z=12.354, P<0.01; Z=6.116, P=0.031). Conclusions:The PGR, G-17 and their combination can all be used to predict SAG in asymptomatic population with high risk of gastric cancer. Compared to those of PGR or G-17 alone, the predictive effect of the combination of them is high.

Correlation of chronic atrophic gastritis with gastric-specific circulating biomarkers

The Diagnostic Value of Serum Trefoil Factor 3 and Pepsinogen combination in Chronic Atrophic Gastritis: A Retrospective Study Based on a Gastric Cancer Screening Cohort in the Community Population

Advances in Clinical and Pathological Diagnosis of Chronic Gastritis

A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study

Predictive value of combined detection of serum pepsinogen and gastrin 17 for atrophic gastritis in population with high-risk of gastric cancer in downtown Shanghai

Effect of Gastrin G-17 Combined with Pepsinogen PGI and PGII on the Early Screening of Gastric Cancer in the Department of Gastroenterology

Combination of Stomach-Specific Indicators with Cancer-Associated Biomarkers in Serum Can Improve the Accuracy to Predict Gastric Cancer

Association of serum pepsinogen with degree of gastric mucosal atrophy in an asymptomatic population

Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers

Determination of serum pepsinogens levels in elderly patients with chronic gastritis and its significance

Abstract C13: Population-based Evaluation of Serum Pepsinogen, Anti-H. Pylori IgG Antibody and Gastrin-17 Tests for Gastric Cancer Screening

Proteomic and serological markers for diagnosing cardia gastric cancer and precursor lesions in a Chinese population

Three-dimensional combined biomarkers assay could improve diagnostic accuracy for gastric cancer

Validation of a blood biomarker for identification of individuals at high risk for gastric cancer.

The Value of Serum Pepsinogen in Screening Chronic Atrophic Gastritis

Pepsinogen I, pepsinogen II, gastrin-17, and Helicobacter pylori serological biomarkers in the diagnosis of precursor lesions of gastric cancer

Study on the effect of serum pepsinogen detection in the screening of chronic gastritis

Effectiveness of serological markers of gastric mucosal atrophy in the gastric precancer screening and in cancer prevention

A Predictive Model of Noncardia Gastric Adenocarcinoma Risk Using Antibody Response to Helicobacter pylori Proteins and Pepsinogen

Expression of growth hormone and its receptor in chronic atrophic gastritis and its clinical significance.

Combination of Serum Test and Questionnaire in Early Gastric Cancer Screening